MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585261 | Name: TA 077

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TA 077 is a derivative of nitrosourea, and useful agent in combination chemotherapy against non-Hodgkin's lymphoma.

Chemical Structure

TA 077
TA 077
CAS#70189-62-7

Theoretical Analysis

MedKoo Cat#: 585261

Name: TA 077

CAS#: 70189-62-7

Chemical Formula: C19H34ClN3O12

Exact Mass: 531.1831

Molecular Weight: 531.94

Elemental Analysis: C, 42.90; H, 6.44; Cl, 6.66; N, 7.90; O, 36.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
TA 077; TA-077; TA077
IUPAC/Chemical Name
Urea, N-(2-chloroethyl)-N'-(4-O-alpha-D-glucopyranosyl-beta-D-glucopyranosyl)-N'-(2-methylpropyl)-N-nitroso-
InChi Key
FTBIJUNCCGTXHL-YMJSIHPXSA-N
InChi Code
InChI=1S/C19H34ClN3O12/c1-8(2)5-22(19(31)23(21-32)4-3-20)17-14(29)13(28)16(10(7-25)33-17)35-18-15(30)12(27)11(26)9(6-24)34-18/h8-18,24-30H,3-7H2,1-2H3/t9-,10-,11-,12+,13-,14-,15-,16-,17-,18-/m1/s1
SMILES Code
O=C(N([C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O[C@@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)O)O)CC(C)C)N(CCCl)N=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 531.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hayashida K, Akaike Y, Nakamura S, Miura Y, Arai Y, Ono Y, Takeyama S. Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). I. Blood and tissue concentrations of a new nitrosourea antitumor agent TA-077 and its metabolite TA-G after intravenous injection of TA-077 in various experimental animals. J Pharmacobiodyn. 1987 Oct;10(10):507-14. PubMed PMID: 3440913. 2: Hayashida K, Miura Y, Arai Y, Takeyama S, Wakui A, Yokoyama M, Kanamaru R, Majima H, Taguchi T, Ohmichi M, et al. Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). III. Pharmacokinetics of a new nitrosourea antitumor agent TA-077 in humans (a phase I study). J Pharmacobiodyn. 1987 Oct;10(10):523-7. PubMed PMID: 3440914. 3: Fujimoto S, Ogawa M. Toxicological study on a new nitrosourea derivative, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea. Jpn J Cancer Res. 1985 Jul;76(7):651-6. PubMed PMID: 3928562. 4: Hayashida K, Oda K, Akaike Y, Arai Y, Takeyama S. Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). II. Hydrolysis by tissue homogenates and drug uptake by tumor cells in vitro. J Pharmacobiodyn. 1987 Oct;10(10):515-22. PubMed PMID: 3326928. 5: Akaike Y, Arai Y, Taguchi H, Satoh H. Effect of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea on experimental tumors. Gan. 1982 Jun;73(3):480-7. PubMed PMID: 7129012. 6: Kobayashi T, Tanaka I, Nishikawa M, Kita K, Matsuoka N, Miwa H, Saitoh M, Tsukada T, Shirakawa S. [Clinical effects of TA-077 in non-Hodgkin's lymphomas]. Gan To Kagaku Ryoho. 1986 Oct;13(11):3194-7. Japanese. PubMed PMID: 3777956. 7: [Phase I study of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). Phase I Study Group]. Gan To Kagaku Ryoho. 1986 Jul;13(7):2425-33. Japanese. PubMed PMID: 3729497. 8: Fujimoto S, Ogawa M. A new nitrosourea derivative TA-077, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea. I. Comparative study on antitumor activity. Cancer Chemother Pharmacol. 1982;9(3):134-9. PubMed PMID: 6218931. 9: Fujimoto S, Ogawa M. A comparison of a new nitrosourea derivative, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea with various antitumor agents with respect to therapeutic ratios in L1210 leukemia systems. J Pharmacobiodyn. 1987 Jul;10(7):341-5. PubMed PMID: 3694427. 10: Akaike Y. Modification of DNA by chloroethylnitrosoureas. Nihon Juigaku Zasshi. 1990 Apr;52(2):443-5. PubMed PMID: 2348611. 11: Kanamaru R, Abe I, Kakuta H, Sato T, Saito S, Ishioka C, Konishi Y, Wakui A. Appearance of anti-cancer activity of a masked compound of nitrosourea TA077, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea in vitro. Sci Rep Res Inst Tohoku Univ Med. 1986 Dec;33(1-4):16-21. PubMed PMID: 3629214.